Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02286622 · ClinicalTrials.gov registry record · Phase 1
A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics
A Phase 1 study of Renal Impairment, sponsored by PTC Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 2
- Study locations
NCT02286622: Completed Phase 1 study of Renal Impairment, sponsored by PTC Therapeutics.
NCT02286622 is a Phase 1 study of Renal Impairment that has completed, run by PTC Therapeutics. The registered enrollment target is 16 participants, below the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target (53% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02286622, a Phase 1 study of Renal Impairment, has completed, sponsored by PTC Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a non-randomized, open-label, single-dose study to compare the PK of 21 desacetyl-DFZ and, if data permits, deflazacort in 8 subjects with ESRD to that of 8 healthy matched control subjects (age, body mass index \[BMI\], and gender).
Primary Outcome
Renal impairment on the pharmacokinetics (PK) of deflazacort in subjects with end-stage renal disease including the area under the plasma concentration time curve, from time 0 to the last measurable non-zero concentration.
Conditions Studied
Interventions
- DRUG Deflazacort
Study Locations (2)
Florida
- University of Miami Division of Clinical Pharmacology - Miami
- Orlando Clinical Research Center - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-12 |
| Est. Completion | 2015-02 |
| Phase | Phase 1 |
What the finished NCT02286622 record still lists
NCT02286622 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 34-participant average among 32 other Renal Impairment trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Renal Impairment appearing as the primary indexed condition, and to 1 intervention - of which Deflazacort is the first listed.
NCT02286622 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT02286622 about?
NCT02286622 is a clinical study titled "A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics". This is a non-randomized, open-label, single-dose study to compare the PK of 21 desacetyl-DFZ and, if data permits, deflazacort in 8 subjects with ESRD to that of 8 healthy matched control subjects (age, body mass index \[BMI\], and gender).
What is the current status of trial NCT02286622?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2014-12. Estimated completion is 2015-02.
What conditions does trial NCT02286622 study?
This clinical trial studies the following conditions: Renal Impairment.
What interventions are being tested in trial NCT02286622?
The interventions under investigation include: Deflazacort (DRUG).
Who is sponsoring clinical trial NCT02286622?
This trial is sponsored by PTC Therapeutics, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02286622 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02286622's enrollment target sits among peer trials
16 28th of 32 higher than 2 of 32 other Renal Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
RECRUITING · Phase 1
-
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
RECRUITING · Phase 1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia